Cannabis Science Orders First Batch of Cannabis Asthma Inhalers

Cannabis Science, Inc. ( OTC PINK : CBIS ), a U.S. company specializing in the development of cannabis based medicines, is happy to announce their first batch order for the previously announced cannabinoid based inhalation medicine for Asthma/COPD has been placed. It is expected to be received by the company within a week and released initially in select California dispensaries and available for delivery. The CBIS MDI Rescue Inhaler dosage is targeting 100 - 200 dose MDI with cannabinoid level variations ranging from 10mg, 25mg, up to 100mg THC, CBD, and other cannabinoid variables as patient/consumer analysis moves further down the road.

Based on State-by-State laws the Company can proceed with studies in the 25+ states approved for medical marijuana, and lay the groundwork for expanding into other states across the nation as legislation changes and more states become legal. This could also be seen as a mechanism to verify the effectiveness of CBD/THC...

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.